Kristine J Steffen

Summary

Affiliation: Neuropsychiatric Research Institute
Country: USA

Publications

  1. doi request reprint Predictors of satisfaction with excess skin and desire for body contouring after bariatric surgery
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota, USA
    Surg Obes Relat Dis 8:92-7. 2012
  2. doi request reprint A prevalence study and description of alli use by patients with eating disorders
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota 58103, USA
    Int J Eat Disord 43:472-9. 2010
  3. ncbi request reprint Emerging drugs for eating disorder treatment
    Kristine J Steffen
    The Neuropsychiatric Research Institute, 120 8th Street South, PO Box 1415, Fargo, ND 58107, USA
    Expert Opin Emerg Drugs 11:315-36. 2006
  4. ncbi request reprint A survey of herbal and alternative medication use among participants with eating disorder symptoms
    Kristine J Steffen
    The Neuropsychiatric Research Institute, Fargo, North Dakota 58107, USA
    Int J Eat Disord 39:741-6. 2006
  5. ncbi request reprint The eating disorders medicine cabinet revisited: a clinician's guide to ipecac and laxatives
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota 58107, USA
    Int J Eat Disord 40:360-8. 2007
  6. doi request reprint An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects
    James L Roerig
    University of North Dakota School of Medicine and Health Sciences, 120 South 8th Street, Fargo, ND 58107 1415, USA
    Biol Psychiatry 65:607-13. 2009
  7. ncbi request reprint Does the avoidance of body and shape concerns reinforce eating disordered attitudes? Evidence from a manipulation study
    Scott G Engel
    Neuropsychiatric Research Institute, USA
    Eat Behav 7:368-74. 2006
  8. doi request reprint A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, ND 58107 1415, USA
    J Clin Psychopharmacol 33:479-84. 2013
  9. doi request reprint Atypical antipsychotic-induced weight gain: insights into mechanisms of action
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA
    CNS Drugs 25:1035-59. 2011
  10. ncbi request reprint A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58107, USA
    J Clin Psychopharmacol 25:413-8. 2005

Research Grants

  1. Bupropion SR as an Anti-Craving Anti-Obesity Agent
    Kristine Steffen; Fiscal Year: 2007

Detail Information

Publications16

  1. doi request reprint Predictors of satisfaction with excess skin and desire for body contouring after bariatric surgery
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota, USA
    Surg Obes Relat Dis 8:92-7. 2012
    ..Furthermore, the present study sought to identify the predictors of which patients might be most desirous of BCS. This was a study conducted at 2 academic research centers...
  2. doi request reprint A prevalence study and description of alli use by patients with eating disorders
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota 58103, USA
    Int J Eat Disord 43:472-9. 2010
    ..This study examined the frequency and characteristics of alli use among patients in eating disorder treatment facilities...
  3. ncbi request reprint Emerging drugs for eating disorder treatment
    Kristine J Steffen
    The Neuropsychiatric Research Institute, 120 8th Street South, PO Box 1415, Fargo, ND 58107, USA
    Expert Opin Emerg Drugs 11:315-36. 2006
    ..An overview of the current pharmacotherapy options for eating disorders is presented with a discussion of the emerging potential treatments...
  4. ncbi request reprint A survey of herbal and alternative medication use among participants with eating disorder symptoms
    Kristine J Steffen
    The Neuropsychiatric Research Institute, Fargo, North Dakota 58107, USA
    Int J Eat Disord 39:741-6. 2006
    ..The purpose of this survey was to collect data on herbal use in participants with eating disorder symptoms...
  5. ncbi request reprint The eating disorders medicine cabinet revisited: a clinician's guide to ipecac and laxatives
    Kristine J Steffen
    Neuropsychiatric Research Institute, Fargo, North Dakota 58107, USA
    Int J Eat Disord 40:360-8. 2007
    ..To describe the frequency of alternative medication use in bulimia nervosa (BN), and to review available nonprescription emetic (ipecac) and laxative products and their potential toxicities...
  6. doi request reprint An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects
    James L Roerig
    University of North Dakota School of Medicine and Health Sciences, 120 South 8th Street, Fargo, ND 58107 1415, USA
    Biol Psychiatry 65:607-13. 2009
    ..Modafinil possesses pharmacologic effects that could influence the weight gain associated with SGAs. The objective of this trial was to determine the effect of modafinil on olanzapine-associated weight gain...
  7. ncbi request reprint Does the avoidance of body and shape concerns reinforce eating disordered attitudes? Evidence from a manipulation study
    Scott G Engel
    Neuropsychiatric Research Institute, USA
    Eat Behav 7:368-74. 2006
    ..The results point to the potential causal effects of attention on eating disordered attitudes, in turn suggesting a basis for possible treatment...
  8. doi request reprint A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, ND 58107 1415, USA
    J Clin Psychopharmacol 33:479-84. 2013
    ..Alteration of the gastrointestinal tract by this procedure suggests a potential for clinically significant alterations in the bioavailability of ingested medications including antidepressants...
  9. doi request reprint Atypical antipsychotic-induced weight gain: insights into mechanisms of action
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA
    CNS Drugs 25:1035-59. 2011
    ..In addition, work in the genetic area promises to result in a better understanding of the variation in risk associated with different individuals...
  10. ncbi request reprint A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND 58107, USA
    J Clin Psychopharmacol 25:413-8. 2005
    ..Thus, a human feeding lab paradigm utilizing a brief exposure to atypical antipsychotics functions as a method to investigate pharmacologically induced weight gain...
  11. ncbi request reprint New targets in the treatment of anorexia nervosa
    James L Roerig
    University of North Dakota, Department of Clinical Neuroscience, School of Medicine and Health Sciences, Grand Forks, USA
    Expert Opin Ther Targets 9:135-51. 2005
    ..Compounds that interact with serotonin, histamine and dopamine receptors may offer unique treatment opportunities. In the future, the manipulation of peptides may add to the therapeutic potential of pharmacotherapy...
  12. doi request reprint A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND, USA
    J Clin Psychopharmacol 28:21-6. 2008
    ..This rejects the hypothesis that ghrelin levels are elevated by the antipsychotic and that this is a potential cause of the weight gain phenomenon...
  13. doi request reprint Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass
    Kristine J Steffen
    Department of Pharmaceutical Sciences, College of Pharmacy, Nursing, and Allied Sciences, North Dakota State University, Fargo, North Dakota, USA
    Surg Obes Relat Dis 9:470-3. 2013
    ..The objective of this study was to examine the rate and extent of alcohol absorption, particularly in the first 10 minutes after a dose of alcohol...
  14. doi request reprint Alcohol abuse and dependence before and after bariatric surgery: a review of the literature and report of a new data set
    Troy W Ertelt
    Department of Psychology, University of North Dakota, Grand Forks, North Dakota, USA
    Surg Obes Relat Dis 4:647-50. 2008
    ..All participant data were collected from patients who had undergone gastric bypass at a Midwestern hospital...
  15. doi request reprint Laxative abuse: epidemiology, diagnosis and management
    James L Roerig
    Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA
    Drugs 70:1487-503. 2010
    ..In the case of an eating disorder, referral for psychiatric treatment is essential to lessen the reliance on laxatives as a method to alter weight and shape...
  16. ncbi request reprint Is multi-impulsive bulimia a distinct type of bulimia nervosa: Psychopathology and EMA findings
    Tricia Cook Myers
    Neuropsychiatric Research Institute, Fargo, North Dakota 58107 1415, USA
    Int J Eat Disord 39:655-61. 2006
    ..To determine if clinically defined multi-impulsive bulimia (MIB) can be validated using an empirical classification approach...

Research Grants2

  1. Bupropion SR as an Anti-Craving Anti-Obesity Agent
    Kristine Steffen; Fiscal Year: 2007
    ..Longer term implications for the results of this study include the potential investigation of this agent as a therapeutic intervention for conditions such as obesity and binge eating disorder. ..